Fenofibrate represses matrix metalloproteinase-2 in endothelial cells

Chia Hui Yang, Yin Cih Chao, Ting Wuan Lin, Jau Kang Huang, Hsi Che Shen, Danny Ling Wang, Shih Chung Chen

Research output: Contribution to journalArticle

Abstract

Fenofibrate is a widely used to ameliorate hyperlipidemia and/or hypercholesterolemia in patients at risk of cardiovascular disease. To date, most of its favorable effects have been attributed to its activation of peroxisome proliferator activated receptor alpha (PPARα), which alters lipid metabolism, contributing to an improved lipid profile. Lines of evidence suggest pleotrophic effects of fenofibrate in cardiovascular system. Given that endothelium is the frontier of vasculature and its dysfunction is prelude of various vascular disorders, e.g. atherosclerosis and arterial stiffening, we investigated the effect of fenofibrate in human endothelial cell (EC) line (Eahy926). Fenofibrate treatment in ECs repressed matrix metalloproteinase-2 (MMP-2) expression in ECs as well as endothelial MMP-2 secretion, associated with decreased MMP-2 activity. In parallel, fenofibrate activated endothelial nitric oxide synthase (eNOS), demonstrated by Ser1177 phosphorylation. Inhibition of eNOS by L-NAME attenuated fenofibrate-suppressed MMP-2, indicating fenofibrate inhibits MMP-2 requires eNOS-derived NO. Collectively, these findings suggest that fenofibrate activates eNOS and increases NO-bioavailability, which in turn suppresses overactivation of MMP-2, contributing to maintenance of endothelial homeostasis. The present study provides a molecular rationale in which fenofibrate exerts vascular protective effects, facilitating the clinical application of its derived medicine.

Original languageEnglish
Pages (from-to)270-276
Number of pages7
JournalJournal of Internal Medicine of Taiwan
Volume21
Issue number4
Publication statusPublished - Aug 2010

Fingerprint

Fenofibrate
Matrix Metalloproteinase 2
Endothelial Cells
Nitric Oxide Synthase Type III
Blood Vessels
PPAR alpha
NG-Nitroarginine Methyl Ester
Cardiovascular System
Hypercholesterolemia
Hyperlipidemias
Lipid Metabolism
Biological Availability
Endothelium
Atherosclerosis
Homeostasis
Cardiovascular Diseases
Maintenance
Phosphorylation
Medicine
Lipids

Keywords

  • Endothelial cell
  • eNOS
  • Fenofibrate
  • MMP-2
  • Nitric oxide

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Yang, C. H., Chao, Y. C., Lin, T. W., Huang, J. K., Shen, H. C., Wang, D. L., & Chen, S. C. (2010). Fenofibrate represses matrix metalloproteinase-2 in endothelial cells. Journal of Internal Medicine of Taiwan, 21(4), 270-276.

Fenofibrate represses matrix metalloproteinase-2 in endothelial cells. / Yang, Chia Hui; Chao, Yin Cih; Lin, Ting Wuan; Huang, Jau Kang; Shen, Hsi Che; Wang, Danny Ling; Chen, Shih Chung.

In: Journal of Internal Medicine of Taiwan, Vol. 21, No. 4, 08.2010, p. 270-276.

Research output: Contribution to journalArticle

Yang, CH, Chao, YC, Lin, TW, Huang, JK, Shen, HC, Wang, DL & Chen, SC 2010, 'Fenofibrate represses matrix metalloproteinase-2 in endothelial cells', Journal of Internal Medicine of Taiwan, vol. 21, no. 4, pp. 270-276.
Yang CH, Chao YC, Lin TW, Huang JK, Shen HC, Wang DL et al. Fenofibrate represses matrix metalloproteinase-2 in endothelial cells. Journal of Internal Medicine of Taiwan. 2010 Aug;21(4):270-276.
Yang, Chia Hui ; Chao, Yin Cih ; Lin, Ting Wuan ; Huang, Jau Kang ; Shen, Hsi Che ; Wang, Danny Ling ; Chen, Shih Chung. / Fenofibrate represses matrix metalloproteinase-2 in endothelial cells. In: Journal of Internal Medicine of Taiwan. 2010 ; Vol. 21, No. 4. pp. 270-276.
@article{82aa52b2c8494bf9808ecaf46e2941ff,
title = "Fenofibrate represses matrix metalloproteinase-2 in endothelial cells",
abstract = "Fenofibrate is a widely used to ameliorate hyperlipidemia and/or hypercholesterolemia in patients at risk of cardiovascular disease. To date, most of its favorable effects have been attributed to its activation of peroxisome proliferator activated receptor alpha (PPARα), which alters lipid metabolism, contributing to an improved lipid profile. Lines of evidence suggest pleotrophic effects of fenofibrate in cardiovascular system. Given that endothelium is the frontier of vasculature and its dysfunction is prelude of various vascular disorders, e.g. atherosclerosis and arterial stiffening, we investigated the effect of fenofibrate in human endothelial cell (EC) line (Eahy926). Fenofibrate treatment in ECs repressed matrix metalloproteinase-2 (MMP-2) expression in ECs as well as endothelial MMP-2 secretion, associated with decreased MMP-2 activity. In parallel, fenofibrate activated endothelial nitric oxide synthase (eNOS), demonstrated by Ser1177 phosphorylation. Inhibition of eNOS by L-NAME attenuated fenofibrate-suppressed MMP-2, indicating fenofibrate inhibits MMP-2 requires eNOS-derived NO. Collectively, these findings suggest that fenofibrate activates eNOS and increases NO-bioavailability, which in turn suppresses overactivation of MMP-2, contributing to maintenance of endothelial homeostasis. The present study provides a molecular rationale in which fenofibrate exerts vascular protective effects, facilitating the clinical application of its derived medicine.",
keywords = "Endothelial cell, eNOS, Fenofibrate, MMP-2, Nitric oxide",
author = "Yang, {Chia Hui} and Chao, {Yin Cih} and Lin, {Ting Wuan} and Huang, {Jau Kang} and Shen, {Hsi Che} and Wang, {Danny Ling} and Chen, {Shih Chung}",
year = "2010",
month = "8",
language = "English",
volume = "21",
pages = "270--276",
journal = "Journal of Internal Medicine of Taiwan",
issn = "1016-7390",
publisher = "臺灣內科醫學會",
number = "4",

}

TY - JOUR

T1 - Fenofibrate represses matrix metalloproteinase-2 in endothelial cells

AU - Yang, Chia Hui

AU - Chao, Yin Cih

AU - Lin, Ting Wuan

AU - Huang, Jau Kang

AU - Shen, Hsi Che

AU - Wang, Danny Ling

AU - Chen, Shih Chung

PY - 2010/8

Y1 - 2010/8

N2 - Fenofibrate is a widely used to ameliorate hyperlipidemia and/or hypercholesterolemia in patients at risk of cardiovascular disease. To date, most of its favorable effects have been attributed to its activation of peroxisome proliferator activated receptor alpha (PPARα), which alters lipid metabolism, contributing to an improved lipid profile. Lines of evidence suggest pleotrophic effects of fenofibrate in cardiovascular system. Given that endothelium is the frontier of vasculature and its dysfunction is prelude of various vascular disorders, e.g. atherosclerosis and arterial stiffening, we investigated the effect of fenofibrate in human endothelial cell (EC) line (Eahy926). Fenofibrate treatment in ECs repressed matrix metalloproteinase-2 (MMP-2) expression in ECs as well as endothelial MMP-2 secretion, associated with decreased MMP-2 activity. In parallel, fenofibrate activated endothelial nitric oxide synthase (eNOS), demonstrated by Ser1177 phosphorylation. Inhibition of eNOS by L-NAME attenuated fenofibrate-suppressed MMP-2, indicating fenofibrate inhibits MMP-2 requires eNOS-derived NO. Collectively, these findings suggest that fenofibrate activates eNOS and increases NO-bioavailability, which in turn suppresses overactivation of MMP-2, contributing to maintenance of endothelial homeostasis. The present study provides a molecular rationale in which fenofibrate exerts vascular protective effects, facilitating the clinical application of its derived medicine.

AB - Fenofibrate is a widely used to ameliorate hyperlipidemia and/or hypercholesterolemia in patients at risk of cardiovascular disease. To date, most of its favorable effects have been attributed to its activation of peroxisome proliferator activated receptor alpha (PPARα), which alters lipid metabolism, contributing to an improved lipid profile. Lines of evidence suggest pleotrophic effects of fenofibrate in cardiovascular system. Given that endothelium is the frontier of vasculature and its dysfunction is prelude of various vascular disorders, e.g. atherosclerosis and arterial stiffening, we investigated the effect of fenofibrate in human endothelial cell (EC) line (Eahy926). Fenofibrate treatment in ECs repressed matrix metalloproteinase-2 (MMP-2) expression in ECs as well as endothelial MMP-2 secretion, associated with decreased MMP-2 activity. In parallel, fenofibrate activated endothelial nitric oxide synthase (eNOS), demonstrated by Ser1177 phosphorylation. Inhibition of eNOS by L-NAME attenuated fenofibrate-suppressed MMP-2, indicating fenofibrate inhibits MMP-2 requires eNOS-derived NO. Collectively, these findings suggest that fenofibrate activates eNOS and increases NO-bioavailability, which in turn suppresses overactivation of MMP-2, contributing to maintenance of endothelial homeostasis. The present study provides a molecular rationale in which fenofibrate exerts vascular protective effects, facilitating the clinical application of its derived medicine.

KW - Endothelial cell

KW - eNOS

KW - Fenofibrate

KW - MMP-2

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=77956654160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956654160&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 270

EP - 276

JO - Journal of Internal Medicine of Taiwan

JF - Journal of Internal Medicine of Taiwan

SN - 1016-7390

IS - 4

ER -